Subject	Consent Agenda – Updated as at 5 December 2022 DRAFT
Agenda item	01d
Category	For Decision

Section A: Introduction

Ten recommendations are being presented to the Board under the Consent Agenda for consideration. Detailed information on the items can be found in the relevant Committee papers in a dedicated folder on BoardEffect at:

https://gavi.boardeffect.co.uk/workrooms/6459/resources/211597

Section B: Actions Requested of the Board

The Gavi Alliance Board is requested to consider the following recommendations from the Gavi Alliance Governance Committee, Audit and Finance Committee and Programme and Policy Committee.

<u>Decision One – Board Chair Reappointment</u>

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) Reappoint José Manuel Barroso as an Unaffiliated Board member through to 31 December 2025; and
- b) Reappoint José Manuel Barroso as Board Chair, with individual signatory authority on behalf of the Gavi Alliance, for a second term through to 31 December 2025.

Decision Two - Board Committee Chair Appointment

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

<u>Appoint</u> Yibing Wu as Chair of the Investment Committee effective 1 January 2023 and until 31 December 2023.

<u>Decision Three – Board and Board Committee Appointments</u>

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) **Appoint** the following Board Members:
 - Mphu Ramatlapeng as an Unaffiliated Board member in the seat currently held by Margaret (Peggy) Hamburg effective 1 January 2023 and until 31 December 2025.
 - **Gabriella Fésüs** as Board Member representing the European Commission on the donor constituency cluster anchored by Germany in the seat currently held by Bernhard Braune of Germany, effective 1 January 2023 and until 31 December 2023.
 - Saad Omer as Board Member representing the research & technical health institutes constituency in the seat currently held by Marta Nunes, effective 1 January 2023 and until 31 December 2023.
 - Andrew (Drew) Otoo as Board Member representing the vaccine industry industrialised countries in the seat currently held by Roger Connor, effective 1 January 2023 and until 31 December 2025.
- b) **Reappoint** the following Board Members:
 - John Arne Røttingen as Board Member representing Norway on the donor constituency cluster anchored by Norway, effective 1 January 2023 and until 31 December 2023.
- c) **Appoint** the following Alternate Board Members:
 - Jérémie Forrat-Jaime as Alternate Board Member to Gabriella Fésüs representing France on the donor constituency cluster anchored by Germany in the seat currently held by Gabriella Fésüs of the European Commission, effective 1 January 2023 and until 31 December 2023.
 - Rhoda Wanyenze as Alternate Board Member so Saad Omer representing the research & technical health institutes constituency in the seat currently held by Saad Omer, effective 1 January 2023 and until 31 December 2025.
 - Joan Benson as Alternate Board Member to Drew Otoo representing the vaccine industry industrialised countries constituency in the seat currently held by An Vermeersch, effective 1 January 2023 and until 31 December 2025.
- d) **Reappoint** the following Alternate Board Members:
 - Francesca Manno as Alternate Board member to Takeshi Akahori representing Italy on the donor constituency cluster anchored by Japan, effective 1 January 2023 and until 31 December 2023.

- **Joris Jurriëns** as Alternate Board member to John Arne Røttingen representing the Netherlands on the donor constituency cluster anchored by Norway, effective 1 January 2023 and until 31 December 2023.
- e) Reappoint the following to the Market-Sensitive Decisions Committee effective 1 January 2023:
 - José Manuel Barroso (Board Chair) until 31 December 2023
 - Gabriella Fésüs (Board Member) until 31 December 2023
- f) **Appoint** the following to the Governance Committee effective 1 January 2023:
 - **Deena Shiff** (Board Member) until 31 December 2023
 - Joan Benson (Alternate Board Member) until 31 July 2023
 - **Jérémie Forrat-Jaime** (Alternate Board Member) until 31 December 2023
- g) **Reappoint** the following to the Governance Committee effective 1 January 2023:
 - John-Arne Røttingen (Board Member) until 31 December 2023
- h) **Reappoint** the following to the Audit and Finance Committee effective 1 January 2023:
 - Joshua Tabah (Alternate Board Member) until 31 December 2023
- i) <u>Appoint</u> the following to the Programme and Policy Committee effective 1 January 2023:
 - Beth Arthy (Board Member) until 31 December 2023
 - Adrien de Chaisemartin (Committee Delegate) until 31 December 2023
 - Hanna Nohynek (Independent Expert) until 31 December 2023
- j) Reappoint the following to the Programme and Policy Committee effective 1 January 2023:
 - Bernhard Braune (Committee Delegate) until 31 December 2023

<u>Decision Four – Independent Review Committee Appointments</u>

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

<u>Appoint</u> as new IRC members the individuals listed in Annex A to Doc 01d, effective immediately and until 31 March 2025.

<u>Decision Five – Amendment to Board and Board Committee Operating Procedures</u>

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

<u>Amend</u> Section 25.1 of the Board and Board Committee Operating Procedures to read as follows:

Appointment and term: The CEO shall be selected by the Board based on merit, in a non-political, open and competitive manner. The CEO shall be appointed to renewable terms of **three** year.

Decision Six – COVAX Facility Governance

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) Dissolve the COVAX Shareholders Council with effect on 31 December 2022;
- b) **Dissolve** the COVAX Consensus Group with effect on 31 December 2022;
- c) **Approve** the amendments to the Terms of Reference of the COVAX AMC Engagement Group as set out in Annex B to Doc 01d;
- d) **Approve** the amendments to the Market-Sensitive Decisions Committee Charter as set out in Annex C to Doc 01d: and
- e) **Extend** the term of the COVID-19 Vaccination Delivery Support Temporary Steering Committee to 30 April 2023

<u>Decision Seven – IFFIm CEPI Arrangement</u>

The Gavi Alliance Audit and Finance Committee <u>recommends</u> to the Gavi Alliance Board that it:

Approve an Assessment Framework exemption to allow funding for CEPI's non-COVID-19 programmes. This exemption shall be applicable only to the transactions related to a single Australian grant (not exceeding AUD 50 million) and a single Spanish grant (not exceeding EUR 75 million) intended for CEPI's support.

Decision Eight – Appointment of Independent Auditor

In accordance with the Gavi Independent Auditor Selection and Evaluation Policy, the Gavi Alliance Audit and Finance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) Reappoint Deloitte SA as the independent auditor of Gavi for the 5-year term from 2023 to 2027; and
- b) Reappoint Deloitte Tax LLP as external tax consultant of Gavi for the 5-year term from 2023 to 2027.

<u>Decision Nine – Amendment of Audit and Investigations Terms of Reference</u>

The Gavi Alliance Audit and Finance Committee <u>reviewed</u> and <u>recommends</u> to the Gavi Alliance Board that it:

<u>Approve</u> the amended Audit and Investigations Terms of Reference attached as Annex D to Doc 01d.

<u>Decision Ten – Gavi support for Inactivated Poliovirus Vaccine</u>

The Gavi Alliance Programme and Policy Committee <u>recommended</u> to the Gavi Alliance Board that it:

<u>Approve</u> continuation of the IPV support approach approved in 2019, namely that countries are exempt from Gavi eligibility and co-financing policies until policies eradication and the withdrawal of bOPV from routine immunisation schedules.